Japan’s PMDA approves Partner’s inhaled Leukine for aPAP

2024-04-04

临床结果上市批准临床2期

Japan’s PMDA approves Partner’s inhaled Leukine for aPAP

Preview

来源: Pharmaceutical Technology

The trial assessed Leukine in 64 subjects with mild to moderate autoimmune pulmonary alveolar proteinosis. Credit: mi_viri / Shutterstock.com.

The Japanese Pharmaceuticals and Medical Device Agency (PMDA) has granted approval for Partner Therapeutics’ Leukine (sargramostim) for inhaled use in treating autoimmune pulmonary alveolar proteinosis (aPAP).

This is the first regulatory approval of an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) product for this indication.

In Japan, Leukine is branded as Sargmalin and was licensed to Nobelpharma in 2022 for certain indications.

Leukine is a glycosylated recombinant human GM-CSF produced by recombinant DNA technology in yeast.

Partner Therapeutics will execute the manufacturing of Sargmalin for Nobelpharma at its facility in Lynnwood, US.

See Also:

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Preview

来源: Pharmaceutical Technology

UK MHRA approves Advanz Pharma antibiotic for complex infections

Preview

来源: Pharmaceutical Technology

The approval is based on the findings from the multicentre, randomised, double-blind, placebo-controlled Phase II PAGE study.

It assessed Leukine in 64 subjects with mild to moderate aPAP.

Subjects were randomised in a 1:1 ratio to receive either Leukine 125μg or a placebo twice a day for seven days, followed by seven days off, over 12 cycles of two weeks.

The trial demonstrated a significant improvement on the primary endpoint, which was the improvement in the alveolar-arterial oxygen gradient from baseline to week 25.

Subjects treated with Leukine also showed greater improvements in serum biomarker secondary endpoints, including KL-6, CEA and monocyte chemoattractant protein-1.

Partner Therapeutics CEO Robert Mulroy stated: “We are grateful to Nobelpharma for their partnership, as well as their deep commitment to making this treatment available to aPAP patients in Japan.

“It has been a pleasure working with their team and we look forward to ensuring the availability of Sargmalin. We also deeply appreciate the commitment of the many patients and doctors who participated in the investigator-initiated clinical trial led by Dr Nakata of Niigata University.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构